Laboratory Co. of America (NYSE:LH) Price Target Lowered to $213.00 at Barclays

Laboratory Co. of America (NYSE:LH) had its target price cut by analysts at Barclays from $234.00 to $213.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an “equal weight” rating on the medical research company’s stock. Barclays‘s price objective indicates a potential upside of 7.07% from the stock’s previous close.

Several other brokerages also recently weighed in on LH. Argus raised Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 price target on the stock in a research report on Monday, March 25th. Evercore ISI began coverage on Laboratory Co. of America in a research report on Friday, February 9th. They set an “in-line” rating and a $240.00 price target on the stock. SVB Leerink began coverage on Laboratory Co. of America in a research report on Monday, February 26th. They set an “outperform” rating and a $260.00 price target on the stock. Robert W. Baird cut their price target on Laboratory Co. of America from $255.00 to $244.00 and set an “outperform” rating on the stock in a research report on Friday. Finally, TheStreet cut Laboratory Co. of America from a “b-” rating to a “c+” rating in a research report on Thursday, February 15th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $243.38.

Laboratory Co. of America Stock Up 0.3 %

Laboratory Co. of America stock traded up $0.58 during mid-day trading on Friday, reaching $198.93. 102,793 shares of the company were exchanged, compared to its average volume of 747,793. The business has a fifty day moving average of $212.06 and a 200 day moving average of $214.69. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.02 and a current ratio of 1.17. The firm has a market cap of $16.74 billion, a P/E ratio of 42.72, a PEG ratio of 1.56 and a beta of 1.01. Laboratory Co. of America has a 12-month low of $174.20 and a 12-month high of $234.09.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $3.68 EPS for the quarter, beating the consensus estimate of $3.46 by $0.22. The firm had revenue of $3.18 billion during the quarter, compared to analyst estimates of $3.12 billion. Laboratory Co. of America had a return on equity of 13.99% and a net margin of 3.24%. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.82 EPS. Research analysts anticipate that Laboratory Co. of America will post 14.84 earnings per share for the current fiscal year.

Insider Buying and Selling at Laboratory Co. of America

In related news, EVP Der Vaart Sandra D. Van sold 259 shares of Laboratory Co. of America stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $222.06, for a total transaction of $57,513.54. Following the sale, the executive vice president now owns 7,637 shares of the company’s stock, valued at approximately $1,695,872.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Glenn A. Eisenberg sold 34,504 shares of the business’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $215.97, for a total transaction of $7,451,828.88. Following the completion of the sale, the chief financial officer now owns 23,595 shares of the company’s stock, valued at approximately $5,095,812.15. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Der Vaart Sandra D. Van sold 259 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $222.06, for a total transaction of $57,513.54. Following the transaction, the executive vice president now directly owns 7,637 shares of the company’s stock, valued at $1,695,872.22. The disclosure for this sale can be found here. Insiders have sold a total of 54,305 shares of company stock worth $11,761,059 in the last quarter. 0.85% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Verdence Capital Advisors LLC lifted its stake in shares of Laboratory Co. of America by 8.9% in the 1st quarter. Verdence Capital Advisors LLC now owns 1,878 shares of the medical research company’s stock worth $410,000 after acquiring an additional 154 shares during the period. Lindbrook Capital LLC lifted its stake in shares of Laboratory Co. of America by 57.1% in the 1st quarter. Lindbrook Capital LLC now owns 1,486 shares of the medical research company’s stock worth $325,000 after acquiring an additional 540 shares during the period. Carmel Capital Partners LLC lifted its stake in shares of Laboratory Co. of America by 1.4% in the 1st quarter. Carmel Capital Partners LLC now owns 5,152 shares of the medical research company’s stock worth $1,126,000 after acquiring an additional 70 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Laboratory Co. of America by 177.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 80,153 shares of the medical research company’s stock worth $17,510,000 after acquiring an additional 51,237 shares during the period. Finally, Valeo Financial Advisors LLC lifted its stake in shares of Laboratory Co. of America by 9.1% in the 1st quarter. Valeo Financial Advisors LLC now owns 7,808 shares of the medical research company’s stock worth $1,624,000 after acquiring an additional 651 shares during the period. 95.94% of the stock is owned by institutional investors and hedge funds.

Laboratory Co. of America Company Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).